BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, November 30, 2023
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Phase I clinical trials: October 2019

Nov. 11, 2019
No Comments
Therapeutic area data reported by biopharma companies on phase I trials in October 2019.
Read More

Phase II clinical trials: October 2019

Nov. 11, 2019
No Comments
Therapeutic area data reported by biopharma companies on phase II trials in October 2019.
Read More

Phase III clinical trials: October 2019

Nov. 11, 2019
No Comments
Therapeutic area data reported by biopharma companies on phase III trials in October 2019.
Read More

The week's biggest gainers and losers

Nov. 11, 2019
No Comments
The top 10 biopharma stock gainers and losers for the week of Nov. 4-8, 2019.
Read More

BioWorld stock report for public biotechnology companies

Nov. 11, 2019
No Comments
All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes.
Read More

In Latin America, Costa Rica is now a med-tech powerhouse

Nov. 11, 2019
By Sergio Held
No Comments
SAN JOSE, Costa Rica – The tiny Latin American country that has become the region's second largest med-tech exporter behind Mexico is betting on disruptive technologies and trends to stay at the technological forefront. Costa Rica's med-tech exports have become one of the nation's most important sources of income and employment, and the country is focused on expanding the sector.
Read More
Targets with arrows

Zimmer Biomet shines in quarter as it continues to execute turnaround

Nov. 6, 2019
By Liz Hollis
No Comments
Warsaw, Ind.-based Zimmer Biomet Holdings Inc. is moving ahead of schedule in terms of its turnaround as it reported revenue of $1.892 billion for the third quarter. That figure represents an increase of 3% over the same period last year, impressing analysts.
Read More

Tandem raises 2019 guidance on strength of its Q3 results

Nov. 6, 2019
By Meg Bryant
No Comments
San Diego-based Tandem Diabetes Care Inc. reported financial results for the third quarter of 2019, with worldwide pump shipments soaring 112% to 17,839 pumps from 8,434 pumps in the same period a year ago. Revenue rose 105% to $94.7 million, up from $46.3 million in the third quarter of 2018.
Read More

Neurology ‘adapting’ to oncology model with new trial design

Nov. 4, 2019
By Marie Powers
No Comments
The oncology field pioneered adaptive trial designs through efforts such as I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), Puma Biotechnology Inc.’s phase II study of the pan-HER tyrosine kinase inhibitor neratinib (Nerlynx) as neoadjuvant therapy in metastatic breast cancer, and the ongoing multidrug, biomarker-driven non-small-cell lung cancer trial known as Lung-MAP.
Read More

Money raised by biotech: 2019 vs. 2018

Nov. 4, 2019
No Comments
Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.
Read More
Previous 1 2 … 171 172 173 174 175 176 177 178 179 180 181 182 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 30, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for November, 30 2023.
  • Joint pain

    Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

    BioWorld Science
    Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • Breast cancer illustration

    Astrazeneca’s AKT inhibitor is approved in breast cancer

    BioWorld
    Along with Enhertu, Astrazeneca plc now has another breast cancer treatment in its portfolio and it may also become a blockbuster. Truqap (capivasertib), combined...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing